Who is sponsoring NCT06836583?

NCT06836583 is sponsored by Donia Hany Saad.

What drugs are being tested in NCT06836583?

Interventions in NCT06836583: trans-nasal pterygopalatine Fossa block, US-guided infrazygomatic percutaneous pterygopalatine Fossa block.

Is NCT06836583 still recruiting?

NCT06836583 is currently completed. Last updated 17 April 2026.

Last reviewed 2026-04-17 · How we verify

NCT06836583

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sphenopalatine Ganglion Block in Endoscopic Transphenoidal Pituitary Gland Surgery

Completed NA Last updated 17 April 2026

What this trial tests

NA trial testing trans-nasal pterygopalatine Fossa block in ULTRASOUND-GUIDED PERCUTANEOUS VERSUS TRANS-NASAL PTERYGOPALATINE FOSSA BLOCK IN ENDOSCOPIC TRANS-SPHENOIDAL PITUITARY GLAND SURGERY in 60 participants. Completed in 15 April 2025.

Timeline

27 February 2025

Primary endpoint
1 April 2025

15 April 2025

Quick facts

Lead sponsor	Donia Hany Saad
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	60
Start date	27 February 2025
Primary completion	1 April 2025
Estimated completion	15 April 2025
Sites	2 locations across Egypt

Drugs / interventions tested

trans-nasal pterygopalatine Fossa block
US-guided infrazygomatic percutaneous pterygopalatine Fossa block

Conditions studied

ULTRASOUND-GUIDED PERCUTANEOUS VERSUS TRANS-NASAL PTERYGOPALATINE FOSSA BLOCK IN ENDOSCOPIC TRANS-SPHENOIDAL PITUITARY GLAND SURGERY — all drugs for ULTRASOUND-GUIDED PERCUTANEOUS VERSUS TRANS-NASAL PTERYGOPALATINE FOSSA BLOCK IN ENDOSCOPIC TRANS-SPHENOIDAL PITUITARY GLAND SURGERY →

Sponsor

Donia Hany Saad

Who can join

Eligibility, any sex, with ULTRASOUND-GUIDED PERCUTANEOUS VERSUS TRANS-NASAL PTERYGOPALATINE FOSSA BLOCK IN ENDOSCOPIC TRANS-SPHENOIDAL PITUITARY GLAND SURGERY. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this study is to compare the effect of bilateral US guided percutaneous PPFB versus transnasal approach on intraoperative anaesthetic requirements (guided by entropy) in patients undergoing endoscopic transsphenoidal resection of pituitary gland surgery in conjucation with general anaesthesia (GA).Secondary aims: total dose of intraoperative dexmedetomidine, intraoperative analgesia (fentanyl), haemodynamics, the surgical field conditions, recovery pattern, and side effects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Ultrasound-guided percutaneous versus trans-nasal pterygopalatine fossa block in endoscopic trans-sphenoidal pituitary gland surgery: a randomized controlled trial.
Saad DH, Ahmed AMM, ElKholy WM, Bakr MM. · · 2026 · PMID 41622136 · DOI 10.1186/s12871-026-03618-0

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06836583 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Donia Hany Saad
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06836583.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing